首页> 外文期刊>NMR in biomedicine >Initial evaluation of hepatic T-1 relaxation time as an imaging marker of liver disease associated with autosomal recessive polycystic kidney disease (ARPKD)
【24h】

Initial evaluation of hepatic T-1 relaxation time as an imaging marker of liver disease associated with autosomal recessive polycystic kidney disease (ARPKD)

机译:肝T-1松弛时间作为常染色体隐性多囊肾疾病(ARPKD)相关的肝脏疾病的影像学标志物的初步评估

获取原文
获取原文并翻译 | 示例
           

摘要

Autosomal recessive polycystic kidney disease (ARPKD) is a potentially lethal multi-organ disease affecting both the kidneys and the liver. Unfortunately, there are currently no non-invasive methods to monitor liver disease progression in ARPKD patients, limiting the study of potential therapeutic interventions. Herein, we perform an initial investigation of T-1 relaxation time as a potential imaging biomarker to quantitatively assess the two primary pathologic hallmarks of ARPKD liver disease: biliary dilatation and periportal fibrosis in the PCK rat model of ARPKD. T-1 relaxation time results were obtained for five PCK rats at 3months of age using a Look-Locker acquisition on a Bruker BioSpec 7.0T MRI scanner. Six three-month-old Sprague-Dawley (SD) rats were also scanned as controls. All animals were euthanized after the three-month scans for histological and biochemical assessments of bile duct dilatation and hepatic fibrosis for comparison. PCK rats exhibited significantly increased liver T-1 values (mean +/- standard deviation=935 +/- 39ms) compared with age-matched SD control rats (847 +/- 26ms, p=0.01). One PCK rat exhibited severe cholangitis (mean T-1=1413ms), which occurs periodically in ARPKD patients. The observed increase in the in vivo liver T-1 relaxation time correlated significantly with three histological and biochemical indicators of biliary dilatation and fibrosis: bile duct area percent (R=0.85, p=0.002), periportal fibrosis area percent (R=0.82, p=0.004), and hydroxyproline content (R=0.76, p=0.01). These results suggest that hepatic T-1 relaxation time may provide a sensitive and non-invasive imaging biomarker to monitor ARPKD liver disease. Copyright (c) 2015 John Wiley & Sons, Ltd.
机译:常染色体隐性隐性多囊肾病(ARPKD)是一种潜在的致死性多器官疾病,同时影响肾脏和肝脏。不幸的是,目前还没有非侵入性方法来监测ARPKD患者的肝脏疾病进展,从而限制了对潜在治疗干预措施的研究。在本文中,我们对T-1弛豫时间进行了初步研究,将其作为潜在的成像生物标记物,以定量评估ARPKD的PCK大鼠模型中ARPKD肝病的两个主要病理标志:胆道扩张和门静脉纤维化。使用Bruker BioSpec 7.0T MRI扫描仪上的Look-Locker采集,对3月龄的五只PCK大鼠获得T-1弛豫时间结果。还扫描了六个三月大的Sprague-Dawley(SD)大鼠作为对照。在为期三个月的肝胆管扩张和肝纤维化的组织学和生化评估扫描后,对所有动物实施安乐死进行比较。与年龄相匹配的SD对照大鼠(847 +/- 26ms,p = 0.01)相比,PCK大鼠的肝脏T-1值显着增加(平均+/-标准偏差= 935 +/- 39ms)。一只PCK大鼠表现出严重的胆管炎(平均T-1 = 1413ms),在ARPKD患者中周期性发生。观察到的体内肝脏T-1弛豫时间的增加与胆道扩张和纤维化的三个组织学和生化指标显着相关:胆管面积百分比(R = 0.85,p = 0.002),门静脉周围纤维化面积百分比(R = 0.82, p = 0.004)和羟脯氨酸含量(R = 0.76,p = 0.01)。这些结果表明,肝脏T-1弛豫时间可能提供敏感且非侵入性的成像生物标记物,以监测ARPKD肝脏疾病。版权所有(c)2015 John Wiley&Sons,Ltd.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号